[1] Centers for Medicare & Medicaid Services. National Health Expenditure Data, Highligts (pdf). Accessed 16 March, 2016, from
https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html
[2] American Society of Clinical Oncology. Focus on cost. Accessed 16 March, 2016, from
http://www.asco.org/practice-research/cancer-care-america-2015/focus-cost
[3] Stenehjem, D.D., Bellows, B.K., Yager, K.M., Jones, J. Kaldate, R., Siebert, U. & Brixner, D.I. (2016). Cost-utility of a prognostic test guiding adjuvant chemotherapy decisions in early-stage non-small cell lung cancer. The Oncologist 2016, 21, 196-204. doi: 10.1634/theoncologist.2015-0162
[4] Sultana, J., Cutroneo, P., Trifioro, G. (2013). Journal of Pharmacology & Pharmacotherapeutics 4, Suppl. 1, S73-S77. doi: 10.4103/0976-500X.120957
[5] Brixner, D., Biltaji, E., Bress, A., Unni, S., Ye, X., Mamiya, T. & Ashcroft, K. (2015). The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. Journal of Medical Economics 19, 3, 213-228. doi: 10.3111/13696998.2015.1110160